Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
ConditionSickle Cell Disease (SCD)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Toulouse
About this trial
Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.
Eligibility criteria
Qualifiers
Sickle cell disease SS or S-béta° thalassemia
Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome
Age > 18 years old
Disqualifiers
Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome)
Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23
Anti-platelets agents
Red blood cell exchange or transfusion < 3 months
Trial design
Treatments tested in this trial
- Not listed
Trial groups
40 Participants
are grouped into 4 trial groupsSponsors and collaborators
Source ClinicalTrials.gov